Eli Lilly (LLY)

What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Wat...

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026.

Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.

Eli Lilly is far from a one-trick pony.

Sen. Elizabeth Warren questioned Trump's trading activity, citing potential conflicts of interest and renewing calls for a stock-trading ban.

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

There is light at the end of the tunnel.

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

This particular sector may suit cautious and aggressive investors.

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.

Eli Lilly's pipeline is an embarrassment of riches.

It is finally bouncing back after several challenging years.

Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.

Huang has lofty expectations for Marvell Technology.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors.

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.